Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Vaccine Production01:23

Vaccine Production

136
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
136
Vaccines01:21

Vaccines

87
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the...
87
Hepatitis01:25

Hepatitis

80
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
80
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

57
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
57
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

22
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
22

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3.

Alimentary pharmacology & therapeutics·2017
Same author

Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin.

Journal of viral hepatitis·2016
Same author

Antiviral response and resistance analysis of treatment-naïve HCV-infected patients receiving single and multiple doses of GS-9190.

Journal of viral hepatitis·2016
Same author

Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies.

Journal of viral hepatitis·2014
Same author

Impact of common risk factors of fibrosis progression in chronic hepatitis C.

Gut·2014
Same author

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.

Journal of viral hepatitis·2013
Same journal

Dupilumab Emerges as an Effective Antibody Therapy for Eosinophilic Esophagitis.

Annual review of medicine·2026
Same journal

CAR T Cell Toxicities and Emerging Treatment Strategies.

Annual review of medicine·2026
Same journal

Transthyretin Amyloid Cardiomyopathy: A Rapidly Evolving Landscape.

Annual review of medicine·2026
Same journal

Accessibility of Somatic Genetic Testing for Cancer Treatment Decisions.

Annual review of medicine·2026
Same journal

Diffuse Parenchymal Lung Disease: Updates in Pathophysiology and Management.

Annual review of medicine·2026
Same journal

Revascularization for Ischemic Cardiomyopathy: Disproving the 45-Year-Old Concept of Hibernating Myocardium.

Annual review of medicine·2026
See all related articles

Related Experiment Video

Updated: Apr 29, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

12.8K

Viral hepatitis vaccines.

I M Jacobson, J L Dienstag

    Annual Review of Medicine
    |January 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Hepatitis B surface antigen particles from plasma create a safe and effective vaccine. Research continues for next-generation hepatitis B vaccines and hepatitis A vaccines, though availability is not immediate.

    More Related Videos

    Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
    07:25

    Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

    Published on: September 25, 2019

    6.6K
    A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
    10:28

    A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

    Published on: June 26, 2020

    9.4K

    Related Experiment Videos

    Last Updated: Apr 29, 2026

    Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
    09:35

    Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

    Published on: February 1, 2017

    12.8K
    Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
    07:25

    Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

    Published on: September 25, 2019

    6.6K
    A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
    10:28

    A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

    Published on: June 26, 2020

    9.4K

    Area of Science:

    • Hepatitis B research
    • Vaccinology
    • Immunology

    Background:

    • Hepatitis B surface antigen particles, purified from carriers, form a plasma-derived vaccine.
    • This vaccine is proven immunogenic, protective, and safe.

    Purpose of the Study:

    • Review current hepatitis B vaccine strategies for pre- and post-exposure prophylaxis.
    • Discuss novel approaches for future hepatitis B vaccine development.
    • Provide an update on hepatitis A vaccine progress.

    Main Methods:

    • Review of existing literature on hepatitis B vaccines.
    • Analysis of current prophylaxis strategies.
    • Overview of emerging vaccine development technologies.

    Main Results:

    • Plasma-derived hepatitis B vaccine demonstrates high efficacy and safety.
    • Established protocols exist for pre- and post-exposure prophylaxis.
    • Next-generation hepatitis B vaccines are under development.
    • Hepatitis A vaccine development shows early progress but is not yet clinically available.

    Conclusions:

    • The current plasma-derived hepatitis B vaccine is a reliable prophylactic measure.
    • Ongoing research promises advanced hepatitis B vaccines.
    • Hepatitis A vaccine development is progressing but requires further time.